Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

No reported Total Equity figures are available to summarize.

Total Equity history

Currency unavailable · from the balance sheet

No Total Equity data reported for this period type.

Total Equity vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
Total Equity for KARD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NAMSNewAmsterdam Pharma Company N.V.Jun 2026$631.42M USD-18.9%+16.7%89.6%
RNAAtrium Therapeutics, Inc.Mar 2026$234.1M USD——80.1%
IKTInhibikase Therapeutics, Inc.Mar 2026$167.62M USD+95.5%+101.8%96.7%
TNYATenaya Therapeutics, Inc.Mar 2026$106.19M USD-11.1%-20.3%78.6%
CYTKCytokinetics, IncorporatedJun 2026-$173.49M USD+52.9%—9.0%
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —+20.9%+16.7%80.1%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.